1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ceralasertib Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Cilostazol Cancer	Emory University	P2	CCC (53)
Duloxetine Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Ensartinib Cancer	Li Zhang, MD	P2	CCC (53)
Eukystol Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Fludeoxyglucose Cancer	Jonsson Comprehensive Cancer Center	P1/2	CCC (53)
Fludrocortisone Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
Human Adenovirus C Serotype 5 Cancer	Thomas Jefferson University	P2	CCC (53)
hx009 Cancer	Hangzhou Hanx Biopharmaceuticals, Ltd.	P2	CCC (53)
Ifa Cancer	Roswell Park Cancer Institute	P2	CCC (53)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Cancer	MedImmune LLC	P2	CCC (53)
Medroxyprogesterone Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
Melatonin Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Methylphenidate Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Mitoxantrone Cancer	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P1/2	CCC (53)
Neratinib Maleate Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Opevesostat Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
Palmidrol Cancer	Academic and Community Cancer Research United	P2	CCC (53)
Pegaspargase Cancer	Chinese Academy of Medical Sciences	P2	CCC (53)
Pertuzumab Cancer	Seoul National University Bundang Hospital	P2	CCC (53)
prl3-zumab Cancer	National Cancer Centre, Singapore	P2	CCC (53)
Retifanlimab Cancer	Incyte Corporation	P1/2	CCC (53)
Sargramostim Cancer	Roswell Park Cancer Institute	P2	CCC (53)
Shr-A1202 Cancer	Shandong Suncadia Medicine Co., Ltd.	P2	CCC (53)
Sotagliflozin Cancer	Icahn School of Medicine at Mount Sinai	P2	CCC (53)
Ssgj-705 Cancer	Shenyang Sunshine Pharmaceutical Co., LTD.	P2	CCC (53)
Survaxm Cancer	Roswell Park Cancer Institute	P2	CCC (53)
Trifluorouracil Tepidopyrimidine Cancer	Sun Yat-sen University	P2	CCC (53)
Utomilumab Cancer	Pfizer	P3	CCC (53)
Z/E 4-Hydroxy Tamoxifen Cancer	Northwestern University	P2	CCC (53)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Cancer	Kura Oncology, Inc.	P2	CCC (52)
Berzosertib Cancer	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	P1/2	CCC (52)
Daptomycin Cancer	M.D. Anderson Cancer Center	P2	CCC (52)
gfh018 Cancer	Genfleet Therapeutics (Shanghai) Inc.	P1/2	CCC (52)
ibi363 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (52)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Cancer	Regeneron Pharmaceuticals	P1/2	CCC (52)
Lidocaine Cancer	Imperial College London	P3	CCC (52)
Lorazepam Cancer	M.D. Anderson Cancer Center	P2	CCC (52)
Nedaplatin Cancer	Wigen Biomedicine Technology (Shanghai) Co., Ltd.	P2/3	CCC (52)
Niraparib Cancer	LaNova Medicines Limited	P2	CCC (52)
Nogitecan Cancer	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	P2	CCC (52)
Pomalidomide Cancer	SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	P1/2	CCC (52)
Ribociclib Cancer	OnKure, Inc.	P1/2	CCC (52)
Teonanacatl Cancer	Roswell Park Cancer Institute	P2	CCC (52)
(+)-Vincristine Cancer	Children's Oncology Group	P2	CCC (52)
YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY) Cancer	Eucure (Beijing) Biopharma Co., Ltd	P1/2	CCC (52)
Apalutamide Cancer	Helsinki University Central Hospital	P2	CCC (51)
Binimetinib Cancer	Roswell Park Cancer Institute	P2	CCC (51)
Ceritinib Cancer	University Health Network, Toronto	P2	CCC (51)
Colchicinum Cancer	University Health Network, Toronto	P2	CCC (51)

Showing 151 to 200 of 1,380 assets

PreviousPage 4 of 28Next